Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Transitional Cell 13Urinary Bladder Neoplasms 12Ureteral Neoplasms 4Neoplasm Metastasis 3Urologic Neoplasms 2Urogenital Neoplasms 2Carcinoma, Renal Cell 2Urologic Diseases 1Urogenital Diseases 1Urinary Bladder Diseases 1Urachal adenocarcinoma 1Salivary Gland Neoplasms 1Renal Pelvis and Ureter Urothelial Carcinoma 1Peripheral Nervous System Diseases 1Penile Squamous Cell Carcinoma (PSCC) 1Penile Neoplasms 1Neoplasms by Site 1Neoplasms 1Muscle-invasive Bladder Cancer 1Muscle Invasive Bladder Urothelial Carcinoma 1Metastatic Urothelial Cancer 1Melanoma 1Male Urogenital Diseases 1Female Urogenital Diseases 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Carcinoma, Adenoid Cystic 1Breast Neoplasms 1Advanced Bladder Cancer 1

Interventions

pembrolizumab 1enfortumab vedotin 1Thioctic Acid 1Tablets 1Music Therapy 1Lenalidomide 1Gloves, Surgical 1Fish Oils 1Fenofibrate 1Exercise 1Dexamethasone 1Cryotherapy 1Corn Oil 1Bortezomib 1Acupuncture Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Peripheral Nervous System Diseases × enfortumab vedotin × Clear all
NCT07484022 2026-06-03

Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer

Generate Biomedicines

Phase 1 Recruiting
37 enrolled
Genitourinary

Carcinoma, Transitional Cell, Peripheral Nervous System Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡